Top Markets
Coin of the day
Neoleukin Therapeutics, Inc. Neoleukin Therapeutics, Inc.

Neoleukin Therapeutics, Inc.

NLTX
Rang in aandelen #26682
Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused... Neoleukin Therapeutics, Inc. (NLTX) is a biopharmaceutical enterprise focused on developing immune-based treatments for conditions such as cancer, inflammatory responses, and autoimmune diseases, utilizing its proprietary protein design technology. The company's leading investigational therapy is NL-201, a novel protein meticulously crafted to emulate the therapeutic effects of the IL-2/IL-15 cytokines. This product candidate is intended for the management of various malignancies, including renal cell carcinoma and melanoma. The organization, founded in 2003, was previously known as Aquinox Pharmaceuticals, Inc. before officially changing its name to Neoleukin Therapeutics, Inc. in August 2019. Its operations are based out of Seattle, Washington.
Aandeelprijs
$3.49
Laatst gesynchroniseerd: 2023-12-19
Marktkapitalisatie
$38.68M
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Neoleukin Therapeutics, Inc. (NLTX)

Categorie

Dividendrendementgeschiedenis voor Neoleukin Therapeutics, Inc. (NLTX)
Het dividendrendement (TTM) van Neoleukin Therapeutics, Inc. (aandelsymbool: NLTX) per 2026 is: 0
Gemiddeld dividendrendement over de afgelopen 5 jaar: 0.00%
Dividendrendementgeschiedenis van Neoleukin Therapeutics, Inc. (NLTX) van 2026 tot 2026
Dividendrendement aan het einde van elk jaar (TTM)
Jaar Dividendrendement Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Dividendrendementen (TTM) van vergelijkbare bedrijven of concurrenten